Swedish Orphan Biovitrum AB (publ) announced a notable increase in net profit for the second quarter of 2026, with earnings attributable to shareholders rising to SEK 1.10 billion from SEK 636 million in the prior year.
Earnings per share climbed to SEK 3.14, compared with SEK 1.83 in the previous year.
Adjusted profit for the period surged to SEK 1.39 billion, up from SEK 817 million a year earlier, and adjusted earnings per share increased to SEK 3.96 from SEK 2.36.
EBITDA expanded to SEK 2.88 billion, compared with SEK 1.90 billion, while adjusted EBITDA grew to SEK 2.79 billion from SEK 2.14 billion.
Operating profit rose to SEK 1.63 billion, versus SEK 1.01 billion in the prior year.
Revenue increased to SEK 7.84 billion, up from SEK 6.18 billion in the previous year.
The company projects full‑year 2026 revenue to grow in the mid‑ to high‑teens percentage range at constant exchange rates, an improvement over its earlier forecast of low double‑digit growth.
It also expects an adjusted EBITA margin in the mid‑ to high‑30 % range of revenue, compared with the prior expectation of mid‑30 %.
On Wednesday, Swedish Orphan Biovitrum AB closed trading 0.44 % higher at SEK 456 on the Stockholm Stock Exchange.
Also Read
- South Korea’s Central Bank Raises Rates After Three Years to Combat Inflation and Debt Risks
- FXTRADING.com Becomes FXT, Built Around a Simple Promise: In Control. When It Gets Real. – Yahoo Finance UK
- US Military Implements Annual Testosterone Screening for Service Members Over 30, Says Defense Secretary
- Cytek Biosciences Establishes New Bellevue Innovation Hub to Accelerate R&D Initiatives
